DDP-4 inhibitors restore memory in obese rats
Several studies have demonstrated that insulin resistance is associated with learning and memory decline. Vildagliptin and sitagliptin, dipeptidyl-peptidase-4 inhibitors, have recently been developed as anti-diabetic drugs. However, the effects of both drugs on cognitive behaviours and brain mitochondrial function in high-fat diet (HFD)-induced insulin-resistant rats have not yet been investigated.
Pintana et al conducted this study on male Wistar rats to test the hypothesis that vildagliptin and sitagliptin can attenuate the impairment of cognitive behaviours and brain mitochondrial dysfunction in rats with ins...
Source: Society for Endocrinology - July 15, 2013 Category: Endocrinology Source Type: news
Januvia Lawsuit News: Panel to Hear Oral Arguments Later This Month...
The Firm is currently investigating Januvia pancreatic cancer lawsuits, as well as Januvia pancreatitis and Januvia thyroid cancer product liability claims.(PRWeb July 08, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10907230.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 9, 2013 Category: Pharmaceuticals Source Type: news
Januvia Lawsuit Website Launched by Bernstein Liebhard LLP to Provide...
The Firm is currently investigating Januvia Lawsuits Involving Alleged Cases of Januvia Pancreatic Cancer, Januvia Pancreatitis, and Januvia Thyroid Cancer.(PRWeb July 03, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10899936.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 4, 2013 Category: Pharmaceuticals Source Type: news
US drugmaker MSD gets interim relief on diabetes drug patent row
The US pharma major alleged the Indian company was coming out with the diabetes drug with Sitagliptin molecule and its derivatives salt in which it has registered patent right. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 25, 2013 Category: Pharmaceuticals Source Type: news
JANUVIA (Sitagliptin) Compared With Sulfonylurea For Patients With Type 2 Diabetes And Mild Renal Impairment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA® (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Diabetes Source Type: news
New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with Type 2 diabetes and mild renal impairment treated with JANUVIA (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia, and with weight loss instead of weight gain. Results were presented at the American Diabetes Association 73rd Scientific Sessions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2013 Category: Global & Universal Source Type: news
Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA...
The Firm is investigating Januvia lawsuits on behalf of alleged victims of Januvia pancreatitis and pancreatic cancer.(PRWeb June 19, 2013)Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb10850018.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 21, 2013 Category: Pharmaceuticals Source Type: news
Bernstein Liebhard LLP Investigating Diabetes Drug Lawsuits Involving...
The Firm is investigating diabetes drug lawsuits on behalf of patients who took Byetta, Januvia, Victoza or similar medications and were diagnosed with pancreatitis, pancreatic cancer or thyroid...(PRWeb June 16, 2013)Read the full story at http://www.prweb.com/releases/diabetes-drug-lawsuit/pancreatic-cancer/prweb10837515.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 16, 2013 Category: Pharmaceuticals Source Type: news
Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued
the following statement regarding this week's NIDDK-NCI Workshop and the
American Diabetes Association’s (ADA) call for an independent review of
data about the safety of incretin-based diabetes medicines, including
GLP-1 analogs and DPP-4 inhibitors such as JANUVIA®
(sitagliptin).
Language:
English
...
Source: Merck.com - Product News - June 12, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Sitagliptin Pretreatment in Diabetics Presenting With ACSSitagliptin Pretreatment in Diabetics Presenting With ACS
Do patients taking DPP-4 inhibitors have better outcomes after ACS compared with patients taking other oral hypoglycemics? Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 11, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Diabetes drugs may be linked to pancreatic cancer
Conclusion
This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas.
The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs.
However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news
Recent Trends in Sitagliptin PrescribingRecent Trends in Sitagliptin Prescribing
This study examined a large claims database to uncover patterns in prescribing antihyperglycemic agents. International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Doctor’s Doubts Imperil Lucrative Diabetes Drugs
Findings by Dr. Peter C. Butler on Merck’s medication Januvia are threatening the future of all drugs in its class, yearly sales of which exceed $9 billion. (Source: NYT Health)
Source: NYT Health - May 30, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Butler, Peter C Pancreatic Cancer Drugs (Pharmaceuticals) Eli Lilly and Company LLY NYSE Merck & Company Inc MRK NYSE Diabetes Bristol Myers Squibb Company BMY NYSE Novo Nordisk A/S NVO NYSE Source Type: news
Cardiovascular Safety of Sitagliptin in Patients With T2DMCardiovascular Safety of Sitagliptin in Patients With T2DM
What is the effect of this DPP-4 inhibitor on cardiovascular outcomes? (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 20, 2013 Category: Consumer Health News Tags: Journal Article Source Type: news
We The People vs. The Pharmaceutical Industry
The pharma industry is in a pickle. It is losing all its friends and handing over sticks to its enemies. In the last few weeks: Novartis lost a major patent dispute in India Merck was denied an injunction against a generic Januvia South Africa announced plans to tighten its patenting requirements to deny (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 30, 2013 Category: Pharmaceuticals Authors: Bernard Munos Source Type: news
